换一批
换一批Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.
第一作者：
Jana,Schlenzka
第一单位：
University Hospital for Internal Medicine, Department of Hematology/Oncology, Heidelberg University Medical School, Heidelberg, Germany.
作者：
主题词
动物(Animals);抗体, 双特异性(Antibodies, Bispecific);抗原, CD19(Antigens, CD19);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);药物评价, 临床前(Drug Evaluation, Preclinical);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);生长抑制物(Growth Inhibitors);人类(Humans);淋巴瘤, B细胞(Lymphoma, B-Cell);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, SCID(Mice, SCID);受体, IgG(Receptors, IgG);重组蛋白质类(Recombinant Proteins);沙立度胺(Thalidomide);肿瘤细胞, 培养的(Tumor Cells, Cultured);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.1097/00001813-200410000-00013
PMID
15457133
发布时间
2019-09-17
- 浏览16
Anti-cancer drugs
915-9页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
